Because we observed the downregulation of LPHN1 in drug-resistant AML cells, we hypothesized that the expression patterns of GAL-9 and TIM-3 would be altered in AML cells with developed MDR. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.